MGMT PROMOTER METHYLATION TUMOR TEST - SDL

Test Information

Name: MGMT PROMOTER METHYLATION TUMOR TEST

Code: 4111612020700-QD

Sample Type: Blood

Turnaround Time (TAT): 14 days

Preparation & Notes

Clinical Significance Prognostication of newly diagnosed glioblastomas. Identifying newly diagnosed glioblastomas that may respond to alkylating chemotherapy (ie, temozolomide). Guiding therapy decision making for newly diagnosed glioblastomas in elderly patients (>60 years). Methodology Methylation-Specific Polymerase Chain Reaction Analysis Preferred Specimen(s) Formalin-fixed, paraffin-embedded tissue block Collection Instructions Tissue block: At least 40% tumor is required for this assay. In general, a 6 mm x 3 mm area of tissue cut at 5-micron thickness is the minimum amount of tissue needed. Tissue should be collected over multiple slides. Slides: Submit one slide stained with hematoxylin and eosin and five unstained, non-baked 5-micron thick sections of tumor. Pathology report must accompany specimen in order for testing to be performed. Transport Container Formalin-fixed, paraffin-embedded tissue block Reject Criteria Specimens decalcified (all methods) • Specimens not formalin-fixed, paraffin-embedded • Bone marrow in EDTA